Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedhelm Leverkus

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Biometrical Journal. Biometrische Zeitschrift|November 4, 2020
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic studyRegina Stegherr, Jan Beyersmann, Valentine Jehl, et al.
Pharmacoeconomics|July 27, 2025
Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology AssessmentsJörg Tomeczkowski, Tanja Heidbrede, Birte Eichinger, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 22, 2014
Chronic pain patients' treatment preferences: a discrete-choice experimentAxel C Mühlbacher, Uwe Junker, Christin Juhnke, et al.
Plos One|June 15, 2021
Population-based incidence and mortality of community-acquired pneumonia in GermanyChristian Theilacker, Ralf Sprenger, Friedhelm Leverkus, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Trials|June 30, 2021
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risksRegina Stegherr, Claudia Schmoor, Jan Beyersmann, et al.
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Biometrical Journal. Biometrische Zeitschrift|November 4, 2020
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic studyRegina Stegherr, Jan Beyersmann, Valentine Jehl, et al.
Pharmacoeconomics|July 27, 2025
Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology AssessmentsJörg Tomeczkowski, Tanja Heidbrede, Birte Eichinger, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 22, 2014
Chronic pain patients' treatment preferences: a discrete-choice experimentAxel C Mühlbacher, Uwe Junker, Christin Juhnke, et al.
Plos One|June 15, 2021
Population-based incidence and mortality of community-acquired pneumonia in GermanyChristian Theilacker, Ralf Sprenger, Friedhelm Leverkus, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Trials|June 30, 2021
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risksRegina Stegherr, Claudia Schmoor, Jan Beyersmann, et al.
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.
Pageof 2